TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03284710

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ALVAC-HIV (vCP2438)
Description: Expresses the gene products ZM96 gp120 (clade C strain) linked to the sequences encoding the HIV-1 transmembrane (TM) anchor sequence of gp41 (28 amino acids clade B LAI strain) and gag and pro (clade B LAI strain); formulated as a lyophilized vaccine for injection at a viral titer ≥ 1 × 10\^6 cell culture infectious dose (CCID)50 and \< 1 × 10\^8 CCID50 (nominal dose of 10\^7 CCID50) and reconstituted with 1mL of sterile sodium chloride solution (NaCl 0.4%) for intramuscular (IM) injection as a single dose

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ALVAC-HIV (vCP2438)
Description: Expresses the gene products ZM96 gp120 (clade C strain) linked to the sequences encoding the HIV-1 transmembrane (TM) anchor sequence of gp41 (28 amino acids clade B LAI strain) and gag and pro (clade B LAI strain); formulated as a lyophilized vaccine for injection at a viral titer ≥ 1 × 10\^6 cell culture infectious dose (CCID)50 and \< 1 × 10\^8 CCID50 (nominal dose of 10\^7 CCID50) and reconstituted with 1mL of sterile sodium chloride solution (NaCl 0.4%) for intramuscular (IM) injection as a single dose

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ALVAC-HIV (vCP2438)
Description: Expresses the gene products ZM96 gp120 (clade C strain) linked to the sequences encoding the HIV-1 transmembrane (TM) anchor sequence of gp41 (28 amino acids clade B LAI strain) and gag and pro (clade B LAI strain); formulated as a lyophilized vaccine for injection at a viral titer ≥ 1 × 10\^6 cell culture infectious dose (CCID)50 and \< 1 × 10\^8 CCID50 (nominal dose of 10\^7 CCID50) and reconstituted with 1mL of sterile sodium chloride solution (NaCl 0.4%) for intramuscular (IM) injection as a single dose

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ALVAC-HIV (vCP2438)
Description: Expresses the gene products ZM96 gp120 (clade C strain) linked to the sequences encoding the HIV-1 transmembrane (TM) anchor sequence of gp41 (28 amino acids clade B LAI strain) and gag and pro (clade B LAI strain); formulated as a lyophilized vaccine for injection at a viral titer ≥ 1 × 10\^6 cell culture infectious dose (CCID)50 and \< 1 × 10\^8 CCID50 (nominal dose of 10\^7 CCID50) and reconstituted with 1mL of sterile sodium chloride solution (NaCl 0.4%) for intramuscular (IM) injection as a single dose
Study: NCT03701529

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: 2-5 mcg/ml of propofol is used for maintenance of anesthesia.
Study: NCT00414037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eszopiclone
Study: NCT03284710

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bivalent Subtype C gp120/MF59
Description: Consists of 2 subtype C recombinant monomeric proteins, TV1.C gp120 Env and 1086.C gp120 Env, each at a dose of 100 mcg, mixed with MF59 adjuvant (an oil-in-water emulsion); delivered as a 0.5 mL IM injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bivalent Subtype C gp120/MF59
Description: Consists of 2 subtype C recombinant monomeric proteins, TV1.C gp120 Env and 1086.C gp120 Env, each at a dose of 100 mcg, mixed with MF59 adjuvant (an oil-in-water emulsion); delivered as a 0.5 mL IM injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bivalent Subtype C gp120 admixed with Al(OH)3 Suspension
Description: Consists of 2 subtype C recombinant monomeric proteins, TV1.C gp120 Env and 1086.C gp120 Env, each at a dose of 100 mcg, admixed with Aluminum Hydroxide Suspension (\~625 mcg aluminum content); delivered as a 0.5 mL IM injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bivalent Subtype C gp120
Description: Consists of 2 subtype C recombinant monomeric proteins, TV1.C gp120 Env and 1086.C gp120 Env, each at a dose of 100 mcg, mixed with sodium chloride for injection, 0.9%; delivered as a 0.5 mL IM injection
Study: NCT00414037

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo-treatment
Study: NCT03040999

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered as an intravenous (IV) infusion every 3 weeks (Q3W)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline or dextrose solution administered as an IV infusion Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 100 mg/m\^2 administered as an IV infusion Q3W

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: 100 mg/m\^2 administered as an IV infusion Q3W

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Accelerated Fractionation (AFX) Radiotherapy
Description: 70 Gray (Gy) given in 35 fractions over 6 weeks

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Accelerated Fractionation (AFX) Radiotherapy
Description: 70 Gray (Gy) given in 35 fractions over 6 weeks

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Standard Fractionation (SFX) Radiotherapy
Description: 70 Gy given in 35 fractions over 7 weeks

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Standard Fractionation (SFX) Radiotherapy
Description: 70 Gy given in 35 fractions over 7 weeks
Study: NCT03978130

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mHealth-CR
Description: Study participants randomized to the intervention (mHealth-CR) arm during the (in-hospital) baseline visit will receive 3 components for their home activity: (1) communication with exercise therapist (in-hospital assessment/counseling followed by regular communication post-discharge), (2) mHealth-CR software, and (3) wearable activity monitoring device.
Study: NCT03519074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-1 combined with cisplatin
Description: Cisplatin 60mg/m2, day 1, every 21 days Oral TS-1 30mg/m2 bd, days 1-14, every 21 days (absolute dose of oral TS-1 will be 40-60mg bd days 1-14, every 21 days, depending on body surface area)
Study: NCT03753334

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: MAG-EPA
Description: 5g/day of omega-3-rich fish oil including 4g of purified monoglycerides EPA, capsules, taken once daily, for 12 months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: 5g/day of placebo (high oleic sunflower oil), capsules, taken once daily, for 12 months
Study: NCT03316196

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COGENT COGNITIVE TRAINING
Description: Computer-administered cognitive training program. COGENT is a modified working memory capacity task designed to train cognitive functioning. COGENT was designed to contain high interference across trials. By requiring repeated practice with utilization of interference control across trials, COGENT is thought to enhance plasticity of cognitive systems and improve performance. That is, training is based on the premise that learning-based neural changes will occur via repeated exposure to a task demanding cognitive control resources

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Non training computer condition
Description: The non-training condition requires participants to complete a similar computer task for the same length of time. The non-training is a modified working memory capacity task designed to be inert. The non-training condition was designed to contain relatively less interference demands across trials. Participants are required to remember the same total number of items as in COGENT (i.e., storage requirements were equivalent), but the task contains relatively less interference inherent in the task.
Study: NCT05070936

Intervention type: OTHER
Group type: OTHER
Intervention: vestibular rehabilitation
Description: Vestibular rehabilitation consisted of a total of 4 sessions, rearranged every 15 days. These exercises were prepared gradually to increase the vestibulo-ocular reflex and vestibulospinal reflex. The following exercises were done with the patients: both sitting and standing gaze stabilization exercises, neck joint range of motion exercises, 20 minutes walks outside, walking backward both open-and-closed eyes, and walking in tandem with both open-and-closed eyes. The therapist gave the patients a home exercise program. It was emphasized that the exercises should be applied as 10 repetitions. After the session, the exercises shown to the patients were explained in written form and given as home exercises. They were also asked to do home exercises 3 times a day, 10 repetitions, for 15 days. Evaluation of the patients was done at the beginning of the first session and the 4th session. Thus, 3 separate exercise sessions and a home exercise program were applied to the patients.
Study: NCT03661723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is a drug (an antibody) that may treat cancer by working with the immune system

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is a drug (an antibody) that may treat cancer by working with the immune system

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is a drug (an antibody) that may treat cancer by working with the immune system

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is a drug (an antibody) that may treat cancer by working with the immune system

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab (also known as Avastin) is designed to prevent or slow down the growth of cancer cells by blocking the growth of blood vessels.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab (also known as Avastin) is designed to prevent or slow down the growth of cancer cells by blocking the growth of blood vessels.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Re-irradiation
Description: Radiotherapy destroys cancer cells using radiation aimed at a cancer from a machine

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Re-irradiation
Description: Radiotherapy destroys cancer cells using radiation aimed at a cancer from a machine

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Re-irradiation
Description: Radiotherapy destroys cancer cells using radiation aimed at a cancer from a machine

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Re-irradiation
Description: Radiotherapy destroys cancer cells using radiation aimed at a cancer from a machine
Study: NCT04237467

Intervention type: OTHER
Intervention: No intervention
Description: There was no intervention.

Intervention type: OTHER
Intervention: No intervention
Description: There was no intervention.
Study: NCT01181388

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: administration of tirofiban by thrombus aspiration catheter in infarct-related artery
Description: a bolus of 10ug/kg tirofiban administration via thrombus aspiration catheter followed by 0.1ug/kg/min for 12 hours after PCI

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: administration of tirofiban by guide catheter
Description: a bolus of 10ug/kg tirofiban administration via guide catheter followed by 0.1ug/kg/min for 12 hours after PCI
Study: NCT04108364

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Voice adaptive training for aphasia
Description: Training with the VoiceAdapt tablet-based therapy app 25 hours (1 hr/day x 5 days/week x 5 weeks)
Study: NCT03985761

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home Telerehabilitation using HoVRS
Description: The Home Virtual Rehabilitation System (HoVRS) integrates a Leap Motion controller, a passive arm support and a suite of custom designed hand rehabilitation simulations. The Leap Motion provides camera based measurement of finger joint positions, allowing for integrated virtual arm and finger training. If the patient's arm is severely impaired, a forearm orthosis that counter-balances gravity to provide graded support to the arm during activity is issued to the subject. In this study, we utilize 3 task-based simulations that train hand manipulation and arm transport. One simulation trains hand opening integrated with pronation and supination, a second trains wrist movement, by presenting targets that subjects navigate a plane over and around buildings to collect, a third simulation, trains shoulder and elbow disassociation in a horizontal plane integrated with hand opening.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home Telerehabilitation using HoVRS
Description: The Home Virtual Rehabilitation System (HoVRS) integrates a Leap Motion controller, a passive arm support and a suite of custom designed hand rehabilitation simulations. The Leap Motion provides camera based measurement of finger joint positions, allowing for integrated virtual arm and finger training. If the patient's arm is severely impaired, a forearm orthosis that counter-balances gravity to provide graded support to the arm during activity is issued to the subject. In this study, we utilize 3 task-based simulations that train hand manipulation and arm transport. One simulation trains hand opening integrated with pronation and supination, a second trains wrist movement, by presenting targets that subjects navigate a plane over and around buildings to collect, a third simulation, trains shoulder and elbow disassociation in a horizontal plane integrated with hand opening.
Study: NCT02945579

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy
Description: Undergo EBRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy
Description: Undergo EBRT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT02860494

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus topical formulation will be applied to the affected areas, once daily, in the evening, for 6 months. Dose regimens will be identical, regardless of the dose-strength of the topical formulation. The topical formulation will be applied onto areas of the face affected by FA by the patient or the patient's parents/legal guardians, while observing standardised precautions (avoiding the eyes, washing the hands after application, etc.).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus topical formulation will be applied to the affected areas, once daily, in the evening, for 6 months. Dose regimens will be identical, regardless of the dose-strength of the topical formulation. The topical formulation will be applied onto areas of the face affected by FA by the patient or the patient's parents/legal guardians, while observing standardised precautions (avoiding the eyes, washing the hands after application, etc.).
Study: NCT02945579

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Whole Breast Irradiation
Description: Undergo whole breast irradiation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Whole Breast Irradiation
Description: Undergo whole breast irradiation
Study: NCT04204447

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hepatitis C Educational Brochure
Description: Subjects will receive information about Hepatitis C through a brochure

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hepatitis C Educational Video
Description: Subjects will receive information about Hepatitis C through a video
Study: NCT02860494

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus topical formulation will be applied to the affected areas, once daily, in the evening, for 6 months. Dose regimens will be identical, regardless of the dose-strength of the topical formulation. The topical formulation will be applied onto areas of the face affected by FA by the patient or the patient's parents/legal guardians, while observing standardised precautions (avoiding the eyes, washing the hands after application, etc.).
Study: NCT04024865

Intervention type: DRUG
Intervention: Domperidone
Description: Women who received a prescription for domperidone (ATC A03FA03) during the six months following delivery.

Intervention type: DRUG
Intervention: No domperidone
Description: Women with no prescription for domperidone during the six months following delivery.
Study: NCT01320189

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Differences in protein content of meals
Description: Differences in protein content (energy percent) of meals

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Differences in protein content of meals
Description: Differences in protein content (energy percent) of meals

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Differences in protein content of meals
Description: Differences in protein content (energy percent) of meals
Study: NCT04645368

Intervention type: DRUG
Intervention: bovhyaluronidase azoxymer
Description: 3000 IU intramuscularly once every 5 days with a course of 15 injections
Study: NCT03703700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zishen Yutai Pill
Description: Patients who undergo the long-term protocol will start taking Zishen Yutai Pill on the day of pituitary suppression, 5g three times a day (Stopping on the first 1-4 days of menstruation), and patients who undergo the antagonist protocol will start taking Zishen Yutai Pill on the 19th to 23rd day of the previous menstruation cycle, 5g three times a day (Stopping on the first 1-4 days of menstruation). The drug will be taken till 2 weeks after transplantation. If the test result is confirmed as biochemical pregnancy (HCG\>50 IU/L), patients continue to take pills till 3 weeks after the clinical pregnancy determined by the ultrasound. If it is determined that the pregnancy test is negative, stop the drug.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients who undergo the long-term protocol will start taking Placebo on the day of pituitary suppression, 5g three times a day (Stopping on the first 1-4 days of menstruation), and patients who undergo the antagonist protocol will start taking Placebo on the 19th to 23rd day of the previous menstruation cycle, 5g three times a day (Stopping on the first 1-4 days of menstruation). The drug will be taken till 2 weeks after transplantation. If the test result is confirmed as biochemical pregnancy (HCG\>50 IU/L), patients continue to take pills till 3 weeks after the clinical pregnancy determined by the ultrasound. If it is determined that the pregnancy test is negative, stop the drug.
Study: NCT03228446

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: filter training
Description: one-week filter training on the computer: computerized visual change detection experiment (selective attention )

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: filter training
Description: one-week filter training on the computer: computerized visual change detection experiment (selective attention )

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: memory training
Description: one-week storage training on the computer: computerized visual change detection experiment (memory storage)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: memory training
Description: one-week storage training on the computer: computerized visual change detection experiment (memory storage)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: no training (control)
Description: no training applied
Study: NCT00702481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab
Description: Patients will receive nimotuzumab 200 mg weekly for 8 weeks. Nimotuzumab will be started together with concurrent chemoradiation, and continued 1 week after the completion of chemoradiation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Concurrent chemotherapy with cisplatin 100 mg/m2 will be given on week 1, 4, and 7 of radiotherapy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Concurrent radiotherapy will be given to the primary tumor and upper neck at 2 Gy per fraction, once a day, five days a week to a total of 70 Gy in 35 fractions in seven weeks.
Study: NCT03735537

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teriparatide Pen Injector

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronic Acid
Description: Any brand or preparation may be used to deliver the required dose of 5mg
Study: NCT02860494

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo topical formulation will be applied to the affected areas, once daily, in the evening, for 6 months, by the patient or the patient's parents/legal guardians, while observing standardised precautions (avoiding the eyes, washing the hands after application, etc.).
Study: NCT00995969

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1.0 g (w/w) placebo cream applied to both target lesions twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CT 327
Description: 1.0 g CT 327 cream will be applied to one target lesion twice daily and 1.0 g placebo cream will be applied to the remaining target lesion twice daily
Study: NCT02927301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody
Description: Atezolizumab was given as 1200 milligrams (mg) via intravenous (IV) infusion on Day 1 of each 21-day cycle.
Study: NCT04961710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hetrombopag Olamine
Description: Hetrombopag Olamine; once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo; once daily
Study: NCT01351909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Description: Given PO